Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Zhou Y, Wu F, Shi Z, Cao J, Tian J, Yao W, et al
Here is a direct comparison from published Phase 2 and Phase 3 data: Semaglutide (Ozempic/Wegovy): Average weight loss of 14.9% at 68 weeks in the STEP 1 trial Tirzepatide (Mounjaro): Average weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial Retatrutide: Average weight loss of 24.2% at 48 weeks in the Phase 2 trial Retatrutide reached a higher percentage of weight loss in fewer weeks
It launched its GLP-1-assisted programme in December 2025 and already has nearly 4,000 users opting for it
The evidence linking GLP-1RAs to ventricular fibrillation and cardiac arrest is limited
Another 2020 publication, The Compromised Intestinal Barrier Induced by Mycotoxins, is a comprehensive review of research linking mycotoxin-induced intestinal damage
Injection site reactions are common but usually mild
US$ 28.14
US$ 22.57
US$ 28.19
US$ 22.01
US$ 20.31
US$ 21.38
US$ 22.41
US$ 23.55
US$ 27.81
US$ 20.16
US$ 21.28
